Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

Table 2

Molecular characteristics per group.

	TKI treated		Naive
	(𝑁=19)		(𝑁=73)
	𝑁	%	𝑁	%
RAS
MUT	1	5.3
WT	18	94.7	73	100.0
EGFR
MUT	3	15.8	1	1.4
WT	16	84.2	56	76.7
Unknown			16	21.9
MET
WT	19	100.0	36	49.3
Unknown			37	50.7
BRAF
WT	19	100.0
Unknown			73	100.0
HER2 exon 20
MUT	2	10.5
WT	17	89.5
Unknown			73	100.0
EGFR (IHC)
0	4	21.1
1			2	2.7
2	3	15.8	8	11.0
3	10	52.6	22	30.1
NE	2	10.5	3	4.1
Unknown			38	52.1
EGFR (FISH)
Amplified	3	15.8	1	1.4
Nonamplified	13	68.4	32	43.8
NE	3	15.8
Unknown			40	54.8